Respiratory
Latest news
198 articles · 20 / page
Severe Nocturnal Hypoxemia, Not Just Obstructive Sleep Apnea, Predicts Reduced Survival in Non-Small Cell Lung Cancer Patients
The NEOSAS-GFPC study demonstrates that severe sleep-related hypoxemia is an independent predictor of increased mortality in NSCLC patients, highlighting the clinical importance of monitoring nocturnal oxygen saturation beyond traditional a
Mapping the Preclinical Phase: The Conserved Sequence of Lung Function Decline in Idiopathic Pulmonary Fibrosis
A landmark study identifies a decade-long conserved sequence of disease progression in IPF, revealing that DLCO decline precedes FVC impairment by years, providing a new framework for early diagnosis and clinical trial design.
Metabolic Synergy: How Obesity and Diabetes Amplify Liver Disease Risk in Alpha-1 Antitrypsin Deficiency
A large-scale longitudinal study reveals that obesity and diabetes synergistically amplify the risk of advanced liver disease in individuals with Alpha-1 Antitrypsin Deficiency (AATD), while also identifying a complex relationship between b
From Compensation to Collapse: How Cardiac Myofibroblasts and UCP2 Genetic Variants Dictate Right Ventricular Fate in PAH
This study identifies the transition of cardiac fibroblasts to myofibroblasts as a critical driver of right ventricular failure in PAH, highlighting the role of UCP2 deficiency and the rs659366 SNP as key clinical indicators of decompensati
Mapping Multimorbidity in Severe Asthma: Defining Replicable Phenotypes to Optimize Personalized Care
This review analyzes findings from the pan-European SHARP registry study, identifying distinct multimorbidity phenotypes in severe asthma. It highlights the impact of steroid-associated and sinonasal clusters on clinical outcomes, advocatin
Optimizing Pediatric Outcomes: Evidence-Based Advancements in Respiratory Delivery, Neonatal Support, and Precision Therapeutics
This review synthesizes practice-changing pediatric research, highlighting how device selection in acute wheezing, automated oxygen titration in neonates, and novel siRNA therapies for hypercholesterolemia are redefining clinical standards
Predicting the Tumble: Recurrent Fall History and Dual-Task Impairment Emerge as Primary Risk Factors in COPD
A new clinical prediction model identifies prior recurrent falls, multimorbidity, and impaired dual-task mobility as key predictors of future falls in patients with COPD, offering a new tool for targeted geriatric intervention in respirator
Tezepelumab Enables Complete Oral Corticosteroid Discontinuation in 50% of Patients with Severe, Uncontrolled Asthma: Results from the WAYFINDER Phase 3b Trial
The WAYFINDER study reveals that tezepelumab significantly reduces OCS dependence in severe asthma, with over half of patients achieving complete discontinuation by week 52 while maintaining asthma control, regardless of baseline inflammato
Serplulimab Plus Chemotherapy Redefines First-Line Standards in Non-Squamous NSCLC: Results from the ASTRUM-002 Trial
The Phase 3 ASTRUM-002 trial demonstrates that adding serplulimab to chemotherapy significantly extends progression-free survival in non-squamous NSCLC, though the further addition of a bevacizumab biosimilar (HLX04) did not provide statist
Redefining Reliever Therapy: Budesonide-Formoterol Outperforms SABA in Controlling Airway Inflammation Among Patients on Maintenance Corticosteroids
The INFORM ASTHMA trial demonstrates that budesonide-formoterol as a reliever significantly reduces Type 2 airway inflammation (FeNO) compared to terbutaline in adults already using maintenance inhaled corticosteroids, establishing a new ev
Aumolertinib Transforms Adjuvant Treatment for EGFR-Mutated Lung Cancer: Significant Survival Gains in the Phase 3 ARTS Trial
The Phase 3 ARTS trial demonstrates that adjuvant aumolertinib significantly improves disease-free survival in patients with resected stage II-IIIB EGFR-mutated NSCLC, reducing the risk of recurrence or death by 83% compared to placebo, wit
Pathophysiological Divergence in Preterm Infants: Early Lung Aeration and Gas Exchange as Predictors of Moderate-to-Severe Bronchopulmonary Dysplasia
A multicentre prospective study reveals that infants developing moderate-to-severe BPD exhibit significant lung aeration and gas exchange deficits as early as day 10, with a critical pathophysiological peak at 26 days of life, regardless of
Beyond the Pill: Why Elexacaftor/Tezacaftor/Ivacaftor Alone Is Not Enough for Peak Physical Fitness in Cystic Fibrosis
An Italian multicentric study reveals that while ETI therapy significantly improves several health markers in Cystic Fibrosis patients, its impact on peak aerobic capacity is modest, emphasizing the indispensable need for structured physica
Beyond Concentration: The MUCQ Score Redefines Chronic Bronchitis Identification
Researchers introduce the Mucin Quantitative Score (MUCQ), a novel metric combining mucin concentration and composition. Validated in the SPIROMICS cohort, MUCQ outperforms traditional total mucin measurements in identifying chronic bronchi
Histologic Subtype Dictates the Survival Benefit of Guideline-Adherent Lymph Node Dissection in T1N0M0 Lung Adenocarcinoma
A large-scale multicenter study reveals that adherence to lymph node dissection guidelines significantly improves survival in early-stage lung adenocarcinoma patients with high-grade histologic patterns, while offering no significant benefi
Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial
The CORAL Phase 2b trial demonstrates that oral nalbuphine extended release significantly reduces objective cough frequency and improves patient-reported symptoms in idiopathic pulmonary fibrosis, addressing a critical unmet need for managi
Scaling the Notes: Feasibility Study Confirms Singing for Lung Health as a Viable Maintenance Strategy Post-Pulmonary Rehabilitation
A multicentre feasibility trial demonstrates that Singing for Lung Health (SLH) is a viable follow-up to pulmonary rehabilitation, showing high retention rates and strong participant enthusiasm for a definitive randomized controlled trial.
Triple-Combination Breakthrough: Penpulimab, Anlotinib, and Chemotherapy Set New Standards for Resectable NSCLC
The ALTER-L043 trial reveals that combining penpulimab, anlotinib, and chemotherapy achieves a staggering 76% major pathologic response rate in resectable non-small cell lung cancer, signaling a potential shift in neoadjuvant treatment para
Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade
Extended follow-up of the NEOpredict-Lung trial demonstrates that short-course preoperative nivolumab, with or without relatlimab, yields high 3-year survival rates and significant nodal downstaging in resectable NSCLC, positioning dual che
High PEEP and Recruitment Manoeuvres Fail to Reduce Pulmonary Complications in One-Lung Ventilation: Insights from the PROTHOR Trial
The international PROTHOR trial reveals that using higher PEEP and recruitment manoeuvres during one-lung ventilation does not decrease postoperative pulmonary complications compared to a lower PEEP strategy, while notably increasing intrao
Browse by specialty
Open language-specific specialty feeds and department pages.